Inactive Instrument

Mallinckrodt Stock price OTC Markets

Equities

MNKKQ

IE00BBGT3753

Pharmaceuticals

Dynamic Chart
Mallinckrodt plc Reports Earnings Results for the Full Year Ended December 29, 2023 CI
Mallinckrodt plc Reports Earnings Results for the Fourth Quarter Ended December 29, 2023 CI
Mallinckrodt plc Provides Earnings Guidance for the Year 2024 CI
Mallinckrodt Appoints Paul O'neill as Executive Vice President, Quality & Operations, Specialty Brands CI
Mallinckrodt plc Announces FDA Clearance of the INOmax® EVOLVE? DS Delivery System and Approval of the INOmax® Mini-Cylinder CI
Mallinckrodt plc Announces Resignation of Sigurdur Olafsson as Chief Executive Officer CI
Mallinckrodt plc Announces Board Changes CI
Drugmaker Mallinckrodt emerges from bankruptcy RE
Drugmaker Mallinckrodt emerges from bankruptcy RE
Mallinckrodt plc Emerged from Bankruptcy CI
Mallinckrodt plc to Present Breadth of Data on Terlivaz (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome At the American Association for the Study of Liver Diseases 2023 Liver Meeting CI
Mallinckrodt plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 29, 2023 CI
Mallinckrodt plc Revises Earnings Guidance for the Full-Year of 2023 CI
Mallinckrodt Presents Latest Health Economics Data on Acthar Gel (Repository Corticotropin Injection) At the Academy of Managed Care Pharmacy Nexus 2023 CI
Rite Aid joins companies going bankrupt amid opioid litigation RE
More news
Managers TitleAgeSince
Chief Executive Officer 55 22-06-24
Director of Finance/CFO 56 19-03-17
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 68 Feb. 01
Chairman 63 22-06-15
Chief Executive Officer 55 22-06-24
More insiders
Mallinckrodt plc develops, manufactures, markets, and distributes branded and generic specialty pharmaceutical products and therapies. The Company operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The Company focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.
More about the company
  1. Stock
  2. Equities
  3. Stock Mallinckrodt plc
  4. Stock Mallinckrodt - OTC Markets